Corporate

Beat Neukom Is the New CFO of Merz Group

Germany,May 23, 2014

The Merz Group is expanding its management team to include yet another executive with an international background. As of July 1, 2014, Beat Neukom will be the Merz Group’s Chief Financial Officer, and therefore a member of the Merz Pharma Board.Beat Neukom can look back on 17 years of international experience in the financial operations of healthcare companies. He held various positions at Johnson & Johnson, most recently as global financial director of the U.S. subsidiary DePuy Mitek. Subsequently, as the CFO of the Swiss biotechnology company Kuros Biosurgery AG, he was responsible for Corporate Finance. Since last year, Beat Neukom is CFO and member of the board of directors of Orthimo AG, a medical equipment research, development and marketing company, whose co-founder he is. After completing a commercial training program, Neukom, a Swiss citizen, studied Business Administration at the Zurich University of Applied Sciences and is a Certified Management Accountant (CMA).

“We are looking forward to working with Beat Neukom and wish him every success in his new position,” said Philip Burchard, the CEO of Merz. “We would also like to thank Dr. Mark Jehle for provisionally coordinating financial operations at Merz.”

About the Merz Pharma Group

Merz is a privately held pharmaceutical company based in Frankfurt, Germany. The company is active in research, development and distribution of innovative products in the areas of aesthetic medicine and dermatology as well as in the field of neurologically induced movement disorders. Merz Aesthetics offers a tailored and harmonized portfolio of products for minimally invasive treatments. With the fillers Radiesse®, Belotero®, Glytone® and the neurotoxin Bocouture®/Xeomin®, the company is an important player in the aesthetics market.

For the treatment of neurologically induced movement disorders, Merz developed Xeomin®, the first botulinum toxin that is free of complex proteins.

In the consumer products segment, Merz Consumer Care is the leading provider of OTC medication, dietary supplements and skincare products in the German-speaking countries with its well-known tetesept® and Merz Spezial® brands.

The Merz Pharma Group employs 2,443 people worldwide (prior year: 2,396). The Company generated revenue of EUR 980.2 million in fiscal year 2012/13 (prior year: EUR 913.1 million).